Skip to main content
. Author manuscript; available in PMC: 2019 Dec 15.
Published in final edited form as: Cancer Res. 2018 Oct 17;78(24):6728–6735. doi: 10.1158/0008-5472.CAN-17-3370

Figure 3. T790M mutation frequency after AICDA activity manipulation.

Figure 3.

A) T790M mutation rate detected after gefitinib exposure (Panel II), is reduced to baseline (Panel I), after combination treatment of gefitinib and Bay11–7802 (Panel III). B) T790M mutation is abrogated in PC9 AICDA CRISPR knock out cell lines (Panels IV, VI) compared to parental PC9 cell line (Panel II) after exposure to 64nM gefitinib. The corresponding DMSO treated controls Panels I, III and V.